Cerus Corporation ( (CERS) ) has released its Q2 earnings. Here is a breakdown of the information Cerus Corporation presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cerus Corporation is a company focused on enhancing blood safety and availability globally, primarily through its INTERCEPT Blood System, which is the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma. The company is headquartered in Concord, California, and is dedicated to safeguarding the world’s blood supply.
In its latest earnings report for the second quarter of 2025, Cerus Corporation announced a total revenue of $60.1 million, with a record product revenue of $52.4 million, marking a 16% increase year-over-year. The company has also raised its full-year 2025 product revenue guidance to a range of $200 million to $203 million.
Key financial highlights include a 19% increase in total revenue compared to the same period last year, driven by strong demand for its INTERCEPT Fibrinogen Complex and global platelet sales. The company also reported a narrowing net loss of $5.7 million and a positive non-GAAP adjusted EBITDA of $0.9 million for the quarter. Additionally, Cerus received a $7.2 million award from the U.S. Department of Defense for developing lyophilized IFC.
Despite the net loss, Cerus Corporation continues to demonstrate strong commercial and financial execution, with increased investments in research and development and selling, general, and administrative expenses to support future growth. The company remains optimistic about its sales trajectory and is committed to achieving positive full-year non-GAAP adjusted EBITDA in 2025.
Looking ahead, Cerus Corporation anticipates continued growth in its product revenue, supported by the successful adoption of its new LED-based INT200 illumination device and advancements in its product development pipeline. The company remains focused on expanding its global presence and enhancing its blood safety technologies.